Improving the quality of life of patients with breast cancer-related lymphoedema by lymphaticovenous anastomosis (LVA): study protocol of a multicentre randomised controlled trial

Joost Wolfs, Jop Beugels, Merel Kimman, Andrzej A Piatkowski de Grzymala, Esther Heuts, Xavier Keuter, Hanneke Tielemans, Dietmar Ulrich, R van der Hulst, Shan Shan Qiu, Joost Wolfs, Jop Beugels, Merel Kimman, Andrzej A Piatkowski de Grzymala, Esther Heuts, Xavier Keuter, Hanneke Tielemans, Dietmar Ulrich, R van der Hulst, Shan Shan Qiu

Abstract

Introduction: Early breast cancer detection and advancements in treatment options have resulted in an increase of breast cancer survivors. An increasing number of women are living with the long-term effects of breast cancer treatment, making the quality of survivorship an increasingly important goal. Breast cancer-related lymphoedema (BCRL) is one of the most underestimated complications of breast cancer treatment with a reported incidence of 20%. A microsurgical technique called lymphaticovenous anastomosis (LVA) might be a promising treatment modality for patients with BCRL. The main objective is to assess whether LVA is more effective than the current standard therapy (conservative treatment) in terms of improvement in quality of life and weather it is cost-effective.

Methods and analysis: A multicentre, randomised controlled trial, carried out in two academic and two community hospitals in the Netherlands. The study population includes 120 women over the age of 18 who have undergone treatment for breast cancer including axillary treatment (sentinel lymph node biopsy or axillary lymph node dissection) and/or axillary radiotherapy, presenting with an early stage lymphoedema of the arm, viable lymphatic vessels and received at least 3 months conservative treatment. Sixty participants will undergo the LVA operation and the other sixty will continue their regular conservative treatment, both with a follow-up of 24 months. The primary outcome is the health-related quality of life. Secondary outcomes are societal costs, quality adjusted life years, cost-effectiveness ratio, discontinuation rate of conservative treatment and excess limb volume.

Ethics and dissemination: The study was approved by the Ethics Committee of Maastricht University Medical Center (METC) on 19 December 2018 (NL67059.068.18). The results of this study will be disseminated in presentations at academic conferences, publications in peer-reviewed journals and other news media.

Trial registration number: NCT02790021; Pre-results.

Keywords: breast surgery; plastic & reconstructive surgery.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart: overview of the study design. LVA, lymphaticovenous anastomosis; NIRF, near-infrared fluorescence imaging.

References

    1. Vignes S, Fau-Prudhomot P, Simon L, et al. . Impact of breast cancer-related lymphedema on working women. Support Care Cancer 2020;28:79–85. 10.1007/s00520-019-04804-2
    1. Fu MR. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management. World J Clin Oncol 2014;5:241–7. 10.5306/wjco.v5.i3.241
    1. Ahmed RL, Schmitz KH, Prizment AE, et al. . Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat 2011;130:981–91. 10.1007/s10549-011-1667-z
    1. Nesvold I-L, Fosså SD, Holm I, et al. . Arm/shoulder problems in breast cancer survivors are associated with reduced health and poorer physical quality of life. Acta Oncol 2010;49:347–53. 10.3109/02841860903302905
    1. Ahmed RL, Prizment A, Lazovich D, et al. . Lymphedema and quality of life in breast cancer survivors: the Iowa women's health study. JCO 2008;26:5689–96. 10.1200/JCO.2008.16.4731
    1. Engel J, Kerr J, Schlesinger-Raab A, et al. . Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat 2003;79:47–57. 10.1023/A:1023330206021
    1. Chachaj A, Małyszczak K, Pyszel K, et al. . Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psychooncology 2010;19:299–305. 10.1002/pon.1573
    1. DiSipio T, Rye S, Newman B, et al. . Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013;14:500–15. 10.1016/S1470-2045(13)70076-7
    1. Dominick SA, Natarajan L, Pierce JP, et al. . The psychosocial impact of lymphedema-related distress among breast cancer survivors in the WHEL study. Psychooncology 2014;23:1049–56. 10.1002/pon.3510
    1. Fu MR, Ridner SH, Hu SH, et al. . Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncology 2013;22:1466–84. 10.1002/pon.3201
    1. Oliveri JM, Day JM, Alfano CM, et al. . Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804. J Cancer Surviv 2008;2:233–42. 10.1007/s11764-008-0065-y
    1. Petrek JA, Senie RT, Peters M, et al. . Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92:1368–77. 10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>;2-9
    1. Voogd AC, Ververs JMMA, Vingerhoets AJJM, et al. . Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg 2003;90:76–81. 10.1002/bjs.4010
    1. Venereologie NvvDe Richtlijn lymfoedeem. Multidisciplinaire evidence-based richtlijn, 2014. Available:
    1. KNL Richtlijn Mammacarcinoom; 2012.
    1. Ashikaga T, Krag DN, Land SR, et al. . Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010;102:111–8. 10.1002/jso.21535
    1. Coriddi M, Khansa I, Stephens J, et al. . Analysis of factors contributing to severity of breast Cancer–Related lymphedema. Ann Plast Surg 2015;74:22–5. 10.1097/SAP.0b013e31828d7285
    1. Monleon S, Murta-Nascimento C, Bascuas I, et al. . Lymphedema predictor factors after breast cancer surgery: a survival analysis. Lymphat Res Biol 2015;13:268–74. 10.1089/lrb.2013.0042
    1. Tsai RJ, Dennis LK, Lynch CF, et al. . The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 2009;16:1959–72. 10.1245/s10434-009-0452-2
    1. Johnson AR, Kimball S, Epstein S, et al. . Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann Plast Surg 2019;82:S234–41.
    1. Grada AA, Phillips TJ. Lymphedema: pathophysiology and clinical manifestations. J Am Acad Dermatol 2017;77:1009–20. 10.1016/j.jaad.2017.03.022
    1. Uzkeser H, Karatay S, Erdemci B, et al. . Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial. Breast Cancer 2015;22:300–7. 10.1007/s12282-013-0481-3
    1. Vignes S, Porcher R, Arrault M, et al. . Long-Term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat 2007;101:285–90. 10.1007/s10549-006-9297-6
    1. McNeely ML, Peddle CJ, Yurick JL, et al. . Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer 2011;117:1136–48.
    1. Dayes IS, Whelan TJ, Julian JA, et al. . Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. JCO 2013;31:3758–63. 10.1200/JCO.2012.45.7192
    1. Koshima I, Inagawa K, Urushibara K, et al. . Supermicrosurgical Lymphaticovenular anastomosis for the treatment of lymphedema in the upper extremities. J Reconstr Microsurg 2000;16:437–42. 10.1055/s-2006-947150
    1. Basta MN, Gao LL, Wu LC. Operative treatment of peripheral lymphedema: a systematic meta-analysis of the efficacy and safety of lymphovenous microsurgery and tissue transplantation. Plast Reconstr Surg 2014;133:905–13. 10.1097/PRS.0000000000000010
    1. Chang DW. Lymphaticovenular bypass for lymphedema management in breast cancer patients: a prospective study. Plast Reconstr Surg 2010;126:752–8. 10.1097/PRS.0b013e3181e5f6a9
    1. Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg 2013;132:1305–14. 10.1097/PRS.0b013e3182a4d626
    1. Damstra RJ, Voesten HGJ, van Schelven WD, et al. . Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat 2009;113:199–206. 10.1007/s10549-008-9932-5
    1. Furukawa H, Osawa M, Saito A, et al. . Microsurgical lymphaticovenous implantation targeting dermal lymphatic backflow using indocyanine green fluorescence lymphography in the treatment of postmastectomy lymphedema. Plast Reconstr Surg 2011;127:1804–11. 10.1097/PRS.0b013e31820cf2e2
    1. Mihara M, Hara H, Hayashi Y, et al. . Upper-Limb lymphedema treated aesthetically with lymphaticovenous anastomosis using indocyanine green lymphography and noncontact vein visualization. J Reconstr Microsurg 2012;28:327–32. 10.1055/s-0032-1311691
    1. Nagase T, Gonda K, Inoue K, et al. . Treatment of lymphedema with lymphaticovenular anastomoses. Int J Clin Oncol 2005;10:304–10. 10.1007/s10147-005-0518-5
    1. Penha TR, Ijsbrandy C, Hendrix NA, et al. . Microsurgical techniques for the treatment of breast cancer-related lymphedema: a systematic review. J Reconstr Microsurg 2013;29:99–106.
    1. Torrisi JS, Joseph WJ, Ghanta S, et al. . Lymphaticovenous bypass decreases pathologic skin changes in upper extremity breast cancer-related lymphedema. Lymphat Res Biol 2015;13:46–53. 10.1089/lrb.2014.0022
    1. Yamamoto Y, Horiuchi K, Sasaki S, et al. . Follow-Up study of upper limb lymphedema patients treated by microsurgical lymphaticovenous implantation (MLVI) combined with compression therapy. Microsurgery 2003;23:21–6. 10.1002/micr.10080
    1. Cornelissen AJM, Beugels J, Ewalds L, et al. . Effect of Lymphaticovenous anastomosis in breast cancer-related lymphedema: a review of the literature. Lymphat Res Biol 2018;16:426–34. 10.1089/lrb.2017.0067
    1. Winters H, Tielemans HJP, Verhulst AC, et al. . The long-term patency of Lymphaticovenular anastomosis in breast Cancer–Related lymphedema. Ann Plast Surg 2019;82:196–200. 10.1097/SAP.0000000000001674
    1. Salgarello M, Mangialardi M, Pino V, et al. . A prospective evaluation of health-related quality of life following Lymphaticovenular anastomosis for upper and lower extremities lymphedema. J Reconstr Microsurg 2018;34:701–7. 10.1055/s-0038-1642623
    1. Giacalone G, Yamamoto T. Supermicrosurgical lymphaticovenous anastomosis for a patient with breast lymphedema secondary to breast cancer treatment. Microsurgery 2017;37:680–3. 10.1002/micr.30139
    1. Cornelissen AJM, Kool M, Lopez Penha TR, et al. . Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life. Breast Cancer Res Treat 2017;163:281–6. 10.1007/s10549-017-4180-1
    1. Winters H, Tielemans HJP, Hameeteman M, et al. . The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema. Breast Cancer Res Treat 2017;165:321–7. 10.1007/s10549-017-4335-0
    1. Masia J, Pons G, Nardulli M. Combined surgical treatment in breast cancer-related lymphedema. J Reconstr Microsurg 2016;32:016–27. 10.1055/s-0035-1544182
    1. Devoogdt N, Van Kampen M, Geraerts I, et al. . Lymphoedema functioning, disability and health questionnaire (Lymph-ICF): reliability and validity. Phys Ther 2011;91:944–57. 10.2522/ptj.20100087
    1. Bouwmans Cea Handleiding iMTA medical cost questionnaire (iMCQ) 2013.
    1. Lopez Penha TR, van Roozendaal LM, Smidt ML, et al. . The changing role of axillary treatment in breast cancer: who will remain at risk for developing arm morbidity in the future? The Breast 2015;24:543–7. 10.1016/j.breast.2015.04.008
    1. Herdman M, Gudex C, Lloyd A, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. 10.1007/s11136-011-9903-x
    1. Kimman ML, Dirksen CD, Lambin P, et al. . Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment. Health Qual Life Outcomes 2009;7:11 10.1186/1477-7525-7-11
    1. M Versteegh M, M Vermeulen K, M A A Evers S, et al. . Dutch tariff for the five-level version of EQ-5D. Value Health 2016;19:343–52. 10.1016/j.jval.2016.01.003
    1. Zorginstituut Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg; 2015.
    1. Zorginstituut Richtlijn voor Het uitvoeren van economische evaluaties in de gezondheidszorg; 2015.
    1. Executive C, Executive Committee . The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology 2016;49:170–84.
    1. Narushima M, Yamamoto T, Ogata F, et al. . Indocyanine green lymphography findings in limb lymphedema. J Reconstr Microsurg 2016;32:72–9. 10.1055/s-0035-1564608

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe